AZN•benzinga•
AstraZeneca Says IMFINZI (durvalumab)-based Regimen Demonstrated Improvement In Event-free Survival In Resectable Early-stage Gastric And Gastroesophageal Junction Cancers
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 7, 2025 by benzinga